This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Datadog (DDOG) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
DDOGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Astera Labs, Inc. (ALAB) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ALABPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Oscar Health, Inc. (OSCR)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
OSCRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes
by Moumi Mondal
GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.
ISRGNegative Net Change ELMDNegative Net Change GMEDPositive Net Change
medical medical-devices
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone
by Zacks Equity Research
NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.
ISRGNegative Net Change WSTPositive Net Change GMEDPositive Net Change NTRANegative Net Change
medical medical-devices
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
by Zacks Equity Research
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
ISRGNegative Net Change WSTPositive Net Change OPKNegative Net Change GMEDPositive Net Change
medical medical-devices
Retractable Stock Slips Post Q1 Earnings, Sales Decline Y/Y
by Zacks Equity Research
RVP's first-quarter 2026 sales decline as mix shifts and tariffs pressure pricing, prompting cost cuts and a push to expand domestic production.
RVPPositive Net Change
earnings medical medical-devices
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
by Zacks Equity Research
QGEN's new QIA Agent platform uses conversational AI to streamline experiment planning and ordering support.
QGENPositive Net Change GMEDPositive Net Change PACBNegative Net Change BDSXNegative Net Change
medical medical-devices
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL's strong Q1 earnings, digital growth and expanding high-tech platform support long-term upside despite rising cost pressures.
ECLPositive Net Change GMEDPositive Net Change PACBNegative Net Change BDSXNegative Net Change
medical medical-devices
Vaso Stock Gains Post Q1 Earnings, Deferred Revenue Grows
by Zacks Equity Research
VASO's first-quarter 2026 revenues dip after its healthcare IT divestiture, but losses narrow and deferred revenue kept climbing.
VASOPositive Net Change
earnings medical medical-devices